CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.

HM-0021005 ER is under clinical development by Hua Medicine Shanghai and currently in Phase I for Type 2 Diabetes.

NA-731 is under clinical development by Biomed Industries and currently in Phase I for Traumatic Brain Injury.

COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

BM-219 is under clinical development by Suzhou Biomissile Biopharmaceutical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.